secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001493152-23-009202
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs reports record FY2022 revenue of $122.6M (+55% YoY), net income $18.5M
--------------------------------------------------------------------------------

- Revenue $122.6M vs $79.0M in 2021 (+55%); net income $18.5M ($1.17 diluted) vs $6.3M ($0.41).
- Adjusted EBITDA $38.6M vs $18.1M; includes $5.9M bad debt write-off from HRSA policy change.
- Cash & equivalents $9.1M, working capital $44.8M; paid $9.3M dividends, repurchased 1.3M shares for $11.3M.
- Subsequent to year-end: acquired exclusive worldwide rights to BE-Smart esophageal cancer test; Board authorized new $6M stock buyback.
- Management expects COVID-19 testing to slow but sees growth in Pharmaloz, Nebula Genomics, and BE-Smart test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/0001493152-23-009202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer